Not applicableStudy completedNCT02285361What this trial is testingGIOTRIF rPMS in Korean Patients With NSCLCWho this might be right forCarcinoma, Non-Small-Cell Lung Boehringer Ingelheim 1,272
Large-scale testing (Phase 3)Study completedNCT02864251What this trial is testingNivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) TherapyWho this might be right forNon-Small-Cell Lung Carcinoma Bristol-Myers Squibb 367
Post-approval studies (Phase 4)Study completedNCT01609543What this trial is testingTarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR MutationsWho this might be right forNon-Squamous Non-Small Cell Lung Cancer Hoffmann-La Roche 62
Testing effectiveness (Phase 2)Looking for participantsNCT05334277What this trial is testingFurmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNAWho this might be right forNon-small Cell Lung Cancer Sun Yat-sen University 280
Not applicableStudy completedNCT02623257What this trial is testingEGFR Mutations on ctDNA in Patients With Advanced NSCLCWho this might be right forNon-small Cell Lung Cancer Stage IIINon-Small-Cell Lung Cancer Metastatic First People's Hospital of Hangzhou 1,055
Not applicableUnknownNCT00815971What this trial is testingMutations in the Epidermal Growth Factor Receptor(EGFR) Gene in Non-Small Cell Lung Carcinoma (NSCLC) and the Relation to Response of Treatment With ErlotinibWho this might be right forNon-Small Cell Lung Cancer Aarhus University Hospital 300
Testing effectiveness (Phase 2)WithdrawnNCT02355431What this trial is testingItacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating MutationsWho this might be right forSolid Tumors and Hematologic MalignancyNSCLC (Non-small Cell Lung Carcinoma) Incyte Corporation
Not applicableLooking for participantsNCT05033691What this trial is testingEvaluate the Efficacy of Osimertinib With Early Intervention SRS Treatment Compared to the Continuation of Osimertinib Alone, in Patients With EGFR Mutated NSCLC and Asymptomatic Brain MetastasesWho this might be right forNSCLCEGFR Gene MutationEGF-R Positive Non-Small Cell Lung Cancer+2 more Hadassah Medical Organization 162
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07343479What this trial is testingSacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain MetastasesWho this might be right forNSCLC (Advanced Non-small Cell Lung Cancer)EGFR Gene MutationsBrain Metastasis Zhejiang Cancer Hospital 45
Not applicableStudy completedNCT01185314What this trial is testingTo Study the Changes in Protein in Lung Cells of Asian Patients With Advanced Non-small Cell Lung Cancer (NSCLC)Who this might be right forNon Small Cell Lung Cancer AstraZeneca 1,270
Not applicableTemporarily pausedNCT05421936What this trial is testingOsimertinib for NSCLC With Uncommon EGFR MutationsWho this might be right forCarcinoma, Non-Small-Cell LungGenes, erbB-1 Sheba Medical Center 100
Testing effectiveness (Phase 2)UnknownNCT04592666What this trial is testingAlmonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung CancerWho this might be right forLung Cancer, Non-small CellEGFR T790MEGFR Gene Mutation Fudan University 226
Large-scale testing (Phase 3)UnknownNCT05104281What this trial is testingOsimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung CancerWho this might be right forCarcinoma, Non-Small-Cell Lung Qingdao Central Hospital 60
Testing effectiveness (Phase 2)WithdrawnNCT01928160What this trial is testingPemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or GefitinibWho this might be right forRecurrent Non-small Cell Lung CancerStage IV Non-small Cell Lung Cancer Vanderbilt-Ingram Cancer Center
Early research (Phase 1)Active Not RecruitingNCT05364073What this trial is testingStudy of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) MutationsWho this might be right forNon-Small Cell Lung Cancer (NSCLC)Metastatic Non-Small Cell Lung CancerAdvanced Non-Small Cell Lung Cancer+3 more ArriVent BioPharma, Inc. 160
Testing effectiveness (Phase 2)Ended earlyNCT00988169What this trial is testingErlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating MutationsWho this might be right forLung Cancer Memorial Sloan Kettering Cancer Center 6
Not applicableStudy completedNCT03059641What this trial is testingTherapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in ChinaWho this might be right forLung NeoplasmsLung Cancer, Nonsmall CellAdenocarcinoma of Lung+1 more Geneplus-Beijing Co. Ltd. 300
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06436144What this trial is testingOsimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLCWho this might be right forNon Small Cell Lung CancerEGFR Gene MutationNon Small Cell Lung Cancer Stage IIIB+1 more Daping Hospital and the Research Institute of Surgery of the Third Military Medical University 93
Testing effectiveness (Phase 2)Looking for participantsNCT07485452What this trial is testingBoosting Osimertinib Blood Brain Barrier PenetrationWho this might be right forNon-Small Cell Lung Cancer Maastricht University Medical Center 7
Early research (Phase 1)Study completedNCT02228369What this trial is testingOral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung CancerWho this might be right forEGFR Mutation Positive Advanced Non Small Cell Lung Cancer AstraZeneca 108